Cubicin and Cardiogenic shock - a phase IV clinical study of FDA data

Summary:

Cardiogenic shock is reported as a side effect among people who take Cubicin (daptomycin), especially for people who are male, 40-49 old, have been taking the drug for < 1 month also take Lasix, and have Endocarditis.

The phase IV clinical study analyzes which people have Cardiogenic shock when taking Cubicin. It is created by eHealthMe based on reports of 7,953 people who have side effects when taking Cubicin from the FDA, and is updated regularly.

What is Cubicin?

Cubicin has active ingredients of daptomycin. It is often used in infection. eHealthMe is studying from 7,991 Cubicin users. Check the latest studies of Cubicin.

What is Cardiogenic shock?

Cardiogenic shock (inadequate circulation of blood) is found to be associated with 925 drugs and 1,162 conditions by eHealthMe. Check the latest studies of Cardiogenic shock.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 26, 2026

7,953 people reported to have side effects when taking Cubicin.
Among them, 23 people (0.29%) have Cardiogenic shock.

Among these 23 people:

How long have people been on Cubicin when they have Cardiogenic shock? *

What is the gender of people who have Cardiogenic shock when taking Cubicin? *

female: 34.78 %
male: 65.22 %

What is the age of people who have Cardiogenic shock when taking Cubicin? *

What are other drugs people take besides Cubicin? *

What are other side effects people have besides Cardiogenic shock? *

Myocarditis (inflammation of heart muscle myocardium): 6 people, 26.09%
Sepsis (a severe blood infection that can lead to organ failure and death): 6 people, 26.09%
Weight Decreased: 5 people, 21.74%
Acute Kidney Failure: 5 people, 21.74%
Weakness: 4 people, 17.39%
Blood Creatine Phosphokinase Increased: 3 people, 13.04%
Drug Ineffective: 3 people, 13.04%
Implant Site Abscess: 3 people, 13.04%
Fever: 3 people, 13.04%
Cardiac Failure Acute: 3 people, 13.04%

What are the existing conditions these people have? *

Endocarditis (inflammation in heart muscle): 6 people, 26.09%
Endocarditis Staphylococcal (an inflammation of the inner layer of the heart by staphylococcal bacterial infection): 3 people, 13.04%
Staphylococcal Bacteraemia (a bacterial infection of blood): 3 people, 13.04%
Heart Attack: 2 people, 8.70%
Hypoglycemia (low blood sugar): 2 people, 8.70%
Bacteraemia (presence of bacteria in the blood): 2 people, 8.70%
Bacterial Infection: 2 people, 8.70%
Cardiac Failure: 2 people, 8.70%
Chronic Kidney Disease: 2 people, 8.70%
Coronary Heart Disease (narrowing or blockage of the coronary arteries): 2 people, 8.70%

* Approximation only. Some reports may have incomplete information.

Do you take Cubicin and have Cardiogenic shock?

- Check whether Cardiogenic shock is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cubicin:

Cubicin (7,991 reports)

Browse all side effects of Cubicin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Cardiogenic shock:

Cardiogenic shock (925 drugs)

Browse all the conditions that are associated with Cardiogenic shock:

Cardiogenic shock (1,162 conditions)

Related publications that referenced our studies

Saliho?lu M, Turhan V, ?nem Y, Ulcay A, Uzun G, Ay H, "Sudden hearing loss in a patient receiving piperacillin/tazobactam and daptomycin for diabetic foot infection", Scandinavian journal of infectious diseases, 2013 Mar .
Saliho?lu M, Turhan V, ?nem Y, Ulcay A, Uzun G, Ay H, "Sudden hearing loss in a patient receiving piperacillin/tazobactam and daptomycin for diabetic foot infection", Scandinavian journal of infectious diseases, 2013 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on daptomycin (the active ingredients of Cubicin) and Cubicin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.